CJC-1295 (no DAC) 10mg.
A little more context.

Start with the source.

GHRH-related analogue offered in separate variants with and without a drug-affinity complex.

Its association with strength is a topic classification, not a claim of proven benefit. Research may involve laboratory models, animal studies, or selected clinical populations. Those findings do not automatically apply to an individual.

Questions worth bringing.

• What type of research supports this topic, and what are its limitations?
• Does the study evaluate this exact compound and formulation?
• What established options are appropriate for my situation?
• What should I track, and who should review it?